Atlas Trials

Recurrent Primary Peritoneal Endometrioid Adenocarcinoma

6 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Primary Peritoneal Endometrioid Adenocarcinoma

RecordFirmDate
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer (NCT05231122)Roswell Park Cancer Institute2024-03-12
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT05920798)Mayo Clinic2023-09-28
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (NCT05295589)National Cancer Institute (NCI)2022-06-30
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NCT04739800)National Cancer Institute (NCI)2021-06-10
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04034927)National Cancer Institute (NCI)2019-12-04
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02839707)National Cancer Institute (NCI)2017-06-23

Track Recurrent Primary Peritoneal Endometrioid Adenocarcinoma automatically

Every clearance here is in the API, with alerts when new ones post.